ABB  Vol.4 No.2 , February 2013
Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice
Abstract: Desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) are promising effective iron chelators for the treatment of iron overload in b-thalassemia patients; nonetheless, their side effects have also been reported. 3-Hydroxypyridinone derivatives are being developed as a safer new chelator and in combined chelation therapy. We evaluated the iron-chelating activity of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in iron-loaded C57BL6 mice. The feeding of a ferrocene-supplemented diet (Fe diet) to mice resulted in iron overload, detectable plasma nontransferrin-bound iron (NTBI) and labile plasma iron (LPI), and increases of red cell membrane iron, plasma malondialdehyde (MDA) and excessive tissue iron deposits. Like DFP, the CM1 lowered the levels of the membrane non-heme iron, the NTBI and LPI (p < 0.05) and the MDA after 3 months of treatment. Administration of the Fe diet and the Fe diet along with the chelators did not change the morphology of the liver and heart. Numerous iron accumulations were observed in the liver and spleen tissues of the Fe dietfed mice, whereas the CM1 reduced such iron deposition. Thus, 1-(N-acetyl-6-aminohexyl)-3-hydro- xypyridin-4-one (CM1) can be considered a candidate bidentate oral iron chelator and is effective in the removal of toxic irons in blood compartment and tissues. The effectiveness and toxicity of the CM1 need to be investigated extensively in thalassemia mice and patients with iron overload.
Cite this paper: Srichairatanakool, S. , Pangjit, K. , Phisalaphong, C. and Fucharoen, S. (2013) Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice. Advances in Bioscience and Biotechnology, 4, 153-163. doi: 10.4236/abb.2013.42023.

[1]   Emerit, J., Beaumont, C. and Trivin, F. (2001) Iron metabolism, free radicals, and oxidative injury. Biomedicine & Pharmacotherapy, 55, 333-339. doi:10.1016/S0753-3322(01)00068-3

[2]   Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. and Cabantchik, Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 104, 1504- 1510. doi:10.1182/blood-2004-02-0630

[3]   Hershko, C. (2007) Iron loading and its clinical implications. American Journal of Hematology, 82, 1147-1148. doi:10.1002/ajh.21070

[4]   Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. and Cabantchik, Z.I. (2003) Labile plas- ma iron in iron overload: Redox activity and susceptibility to chelation. Blood, 102, 2670-2677. doi:10.1182/blood-2003-03-0807

[5]   Hershko, C.M., Link, G.M., Konijn, A.M. and Cabantchik, Z.I. (2005) Iron chelation therapy. Current Hematology Reports, 4, 110-116.

[6]   Taher, A.T., Musallam, K.M. and Inati, A. (2009) Iron overload: Consequences, assessment, and monitoring. He- moglobin, 33, S46-57. doi:10.3109/03630260903346676

[7]   Miskin, H., Yaniv, I., Berant, M., Hershko, C. and Tamary, H. (2003) Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European Journal of Haematology, 70, 398-403. doi:10.1034/j.1600-0609.2003.00075.x

[8]   Modell, B., Khan, M. and Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet, 355, 2051-2052. doi:10.1016/S0140-6736(00)02357-6

[9]   Lau, Y.L., Chan, L.C., Chan, Y.Y., Ha, S.Y., Yeung, C.Y., Waye, J.S. and Chui, D.H. (1997) Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong—Implications for population screening. The New England Journal of Medicine, 336, 1298-1301. doi:10.1056/NEJM199705013361805

[10]   Economou, M., Printza, N., Teli, A., Tzimouli, V., Tsatra, I., Papachristou, F. and Athanassiou-Metaxa, M. (2010) Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematologica, 123, 148-152. doi:10.1159/000287238

[11]   Pippard, M.J. (1987) Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobino- pathies. Acta Haematologica, 78, 206-211. doi:10.1159/000205876

[12]   Collins, A.F., Fassos, F.F., Stobie, S., Lewis, N., Shaw, D., Fry, M., Templeton, D.M., McClelland, R.A., Koren, G. and Olivieri, N.F. (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl- 3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood, 83, 2329-2333.

[13]   Freeman, A.P., Giles, R.W., Berdoukas, V.A., Talley, P.A. and Murray, I.P. (1989) Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clinical and Laboratory Haematology, 11, 299- 307. doi:10.1111/j.1365-2257.1989.tb00227.x

[14]   Brittenham, G.M. (2003) Iron chelators and iron toxicity. Alcohol, 30, 151-158. doi:10.1016/S0741-8329(03)00101-0

[15]   Peterson, C.M., Graziano, J.H., Grady, R.W., Jones, R.L., Vlassara, H.V., Canale, V.C., Miller, D.R. and Cerami, A. (1976) Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major. British Journal of Haematology, 33, 477-485. doi:10.1111/j.1365-2141.1976.tb03566.x

[16]   Peterson, C.M., Graziano, J.H., Grady, R.W., Jones, R.L., Markenson, A., Lavi, U., Canale, V., Gray, G.F., Cerami, A. and Miller, D.R. (1979) Chelation therapy in beta- thalassemia major: A one-year double blind study of 2,3- dihydroxybenzoic acid. Experimental Hematology, 7, 74- 80.

[17]   Pippard, M.J., Jackson, M.J. and Modell, C.B. (1988) Subcutaneous diethylene triamine pentaacetic acid: Comparison with desferrioxamine in thalassemic patients with iron overload. Birth Defects Original Article Series, 23, 105-109.

[18]   Grady, R.W., Salbe, A.D., Hilgartner, M.W. and Giardina, P.J. (1994) Results from a phase I clinical trial of HBED. Advances in Experimental Medicine and Biology, 356, 351-359. doi:10.1007/978-1-4615-2554-7_37

[19]   Rai, B.L., Dekhordi, L.S., Khodr, H., Jin, Y., Liu, Z. and Hider, R.C. (1998) Synthesis, physicochemical properties, and evaluation of N-substituted-2-al kyl-3-hydroxy-4(1H)- pyridinones. Journal of Medicinal Chemistry, 41, 3347- 3359. doi:10.1021/jm9707784

[20]   Srichairatanakool, S., Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalpong, C. and Fucharoen, S. (2006) Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin, 30, 311-327. doi:10.1080/03630260600642666

[21]   Thephinlap, C., Ounjaijean, S., Khansuwan, U., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2007) Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and ery- throcyte oxidative stress. Medicinal Chemistry, 3, 289- 296. doi:10.2174/157340607780620608

[22]   Srichairatanakool, S., Thephinlap, C., Phisalaphong, C., Porter, J.B. and Fucharoen, S. (2007) Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Medicinal Chemistry, 3, 469-474. doi:10.2174/157340607781745447

[23]   Thephinlap, C., Phisalaphong, C., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2009) Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Medicinal Chemistry, 5, 474- 482. doi:10.2174/157340609789117912

[24]   Saewong, T., Ounjaijean, S., Mundee, Y., Pattanapanyasat, K., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2010) Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Medicinal Chemistry, 6, 57-64. doi:10.2174/157340610791321479

[25]   Bergeron, R.J., Wiegand, J. and Brittenham, G.M. (1999) HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood, 93, 370-375.

[26]   Porter, J.B. (1996) Evaluation of new iron chelators for clinical use. Acta Haematologic, 95, 13-25. doi:10.1159/000203852

[27]   Srichairatanakool, S., Pangjit, K. and Phisalaphong, C. (2009) Characterization and investigation of chelating activity of a novel iron chelator: 1-(N-acetyl-6-aminohexyl) -3-hydroxypyridin-4-one. Thailand Patent No. 0901000 799.

[28]   Pangjit, K., Banjerdpongchai, R., Phisalaphong, C., Fu- charoen, S. and Srichairatanakool, S. (2012) Efficacy of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in treatment of iron-loaded hepatocyte cultures. Advances in Bioscience and Biotechnology, 3, 1060-1067. doi:10.4236/abb.2012.327129

[29]   Jamsai, D., Zaibak, F., Khongnium, W., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Fucharoen, S., Williamson, R. and Ioannou, P.A. (2005) A humanized mouse model for a common beta0-thalassemia mutation. Genomics, 85, 453-461. doi:10.1016/j.ygeno.2004.11.016

[30]   Jamsai, D., Zaibak, F., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Peters, H., Fucharoen, S., Williamson, R. and Ioannou, P.A. (2006) A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. Genomics, 88, 309-315. doi:10.1016/j.ygeno.2006.03.009

[31]   Valerio Jr., L.G. and Petersen, D.R. (2000) Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron (Ferrocene) to mice: Cellular, biochemical, and molecular aspects. Experimental and Molecular Pathology, 68, 1-12. doi:10.1006/exmp.1999.2278

[32]   Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalapong, C., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2008) Effect of green tea on iron status and oxidative stress in iron-loaded rats. Medicinal Chemistry, 4, 365-370. doi:10.2174/157340608784872316

[33]   Kuross, S.A., Rank, B.H. and Hebbel, R.P. (1988) Excess heme in sickle erythrocyte inside-out membranes: Possible role in thiol oxidation. Blood, 71, 876-882.

[34]   Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254. doi:10.1016/0003-2697(76)90527-3

[35]   Singh, S., Hider, R.C. and Porter, J.B. (1990) A direct method for quantification of non-transferrin-bound iron. Analytical Biochemistry, 186, 320-323. doi:10.1016/0003-2697(90)90088-Q

[36]   Rebouche, C.J., Wilcox, C.L. and Widness, J.A. (2004) Microanalysis of non-heme iron in animal tissues. Journal of Biochemical and Biophysical Methods, 58, 239- 251. doi:10.1016/j.jbbm.2003.11.003

[37]   Grotto, D., Santa Maria, L.D., Boeira, S., Valentini, J., Charao, M.F., Moro, A.M., Nascimento, P.C., Pomblum, V.J. and Garcia, S.C. (2007) Rapid quantification of ma- londialdehyde in plasma by high performance liquid chromatography-visible detection. Journal of Pharmaceutical and Biomedical Analysis, 43, 619-624. doi:10.1016/j.jpba.2006.07.030

[38]   Gomes, A.T., Bastos, C.G., Afonso, C.L., Medrado, B.F. and Andrade, Z.A. (2006) How variable are hydroxy- proline determinations made in different samples of the same liver? Clinical Biochemistry, 39, 1160-1163. doi:10.1016/j.clinbiochem.2006.08.002

[39]   Bancroft, J.S.A. (1982) Theory and practice of histological techniques. 2nd Edition, Churchill-Livingston, New York, 131-135.

[40]   Aisen, P., Enns, C. and Wessling-Resnick, M. (2001) Chemistry and biology of eukaryotic iron metabolism. The International Journal of Biochemistry & Cell Biology, 33, 940-959. doi:10.1016/S1357-2725(01)00063-2

[41]   Crichton, R.R. and Ward, R.J. (2003) An overview of iron metabolism: Molecular and cellular criteria for the selection of iron chelators. Current Medicinal Chemistry, 10, 997-1004. doi:10.2174/0929867033457566

[42]   Conrad, M.E. and Umbreit, J.N. (2002) Pathways of iron absorption. Blood Cells, Molecules and Diseases, 29, 336- 355. doi:10.1006/bcmd.2002.0564

[43]   Pippard, M.J., Callender, S.T., Warner, G.T. and Weatherall, D.J. (1979) Iron absorption and loading in beta-tha- lassaemia intermedia. Lancet, 2, 819-821. doi:10.1016/S0140-6736(79)92175-5

[44]   McLaren, G.D., Nathanson, M.H., Jacobs, A., Trevett, D. and Thomson, W. (1991) Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. Journal of Laboratory and Clinical Medicine, 117, 390-401.

[45]   Raja, K.B., Simpson, R.J. and Peters, T.J. (1994) Intestinal iron absorption studies in mouse models of iron- overload. British Journal of Haematology, 86, 156-162. doi:10.1111/j.1365-2141.1994.tb03267.x

[46]   Longueville, A. and Crichton, R.R. (1986) An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Biochemical Pharmacology, 35, 3669-3678. doi:10.1016/0006-2952(86)90650-7

[47]   Braumann, A., Wulfhekel, U., Dullmann, J. and Nielsen, P. (1992) Iron overload of the bone marrow by trime- thylhexanoyl-ferrocene in rats. Acta Anatomica (Basel), 144, 285-295. doi:10.1159/000147318

[48]   Florence, A., Ward, R.J., Peters, T.J. and Crichton, R.R. (1992) Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat. Biochemical Pharmacology, 44, 1023-1027. doi:10.1016/0006-2952(92)90363-N

[49]   Van Wyck, D.B., Popp, R.A., Foxley, J., Witte, M.H., Witte, C.L. and Crosby, W.H. (1984) Spontaneous iron overload in alpha-thalassemic mice. Blood, 64, 263-266.

[50]   Garrick, L.M., Strano-Paul, L.A., Hoke, J.E., Kirdani- Ryan, L.A., Alberico, R.A., Everett, M.M., Bannerman, R.M. and Garrick, M.D. (1989) Tissue iron deposition in untransfused beta-thalassemic mice. Experimental Hema- tology, 17, 423-428.

[51]   Chua, A.C., Ingram, H.A., Raymond, K.N. and Baker, E. (2003) Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells. European Journal of Biochemistry, 270, 1689- 1698. doi:10.1046/j.1432-1033.2003.03525.x

[52]   Chua, A.C., Olynyk, J.K., Leedman, P.J. and Trinder, D. (2004) Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood, 104, 1519-1525. doi:10.1182/blood-2003-11-3872

[53]   Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T. and Evans, P. (2005) Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Annals of the New York Academy of Sciences, 1054, 155- 168. doi:10.1196/annals.1345.018

[54]   Liuzzi, J.P., Aydemir, F., Nam, H., Knutson, M.D. and Cousins, R.J. (2006) Zip14 (Slc39a14) mediates non- transferrin-bound iron uptake into cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 13612-13617. doi:10.1073/pnas.0606424103

[55]   Shinar, E. and Rachmilewitz, E.A. (1990) Oxidative denaturation of red blood cells in thalassemia. Seminars in Hematology, 27, 70-82.

[56]   Scott, M.D., van den Berg, J.J., Repka, T., Rouyer-Fessard, P., Hebbel, R.P., Beuzard, Y. and Lubin, B.H. (1993) Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. Journal of Clinical Investigation, 91, 1706-1712. doi:10.1172/JCI116380

[57]   Browne, P.V., Shalev, O., Kuypers, F.A., Brugnara, C., Solovey, A., Mohandas, N., Schrier, S.L. and Hebbel, R.P. (1997) Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. Jour- nal of Clinical Investigation, 100, 1459-1464. doi:10.1172/JCI119666

[58]   Andrews, N.C. (1999) Disorders of iron metabolism. The New England Journal of Medicine, 341, 1986-1995. doi:10.1056/NEJM199912233412607

[59]   Bacon, B.R. and Britton, R.S. (1989) Hepatic injury in chronic iron overload. Role of lipid peroxidation. Che- mico-Biological Interactions, 70, 183-226. doi:10.1016/0009-2797(89)90045-8

[60]   Jensen, P.D. (2004) Evaluation of iron overload. British Journal of Haematology, 124, 697-711. doi:10.1111/j.1365-2141.2004.04838.x

[61]   Ramm, G.A. and Ruddell, R.G. (2005) Hepatotoxicity of iron overload: Mechanisms of iron-induced hepatic fibrogenesis. Seminars in Liver Disease, 25, 433-449. doi:10.1055/s-2005-923315

[62]   Popper, H. and Uenfriend, S. (1970) Hepatic fibrosis. Correlation of biochemical and morphologic investigations. The American Journal of Medicine, 49, 707-721. doi:10.1016/S0002-9343(70)80135-8

[63]   Kushner, J.P., Porter, J.P. and Olivieri, N.F. (2001) Secondary iron overload. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 47-61.

[64]   Weatherall, D.J. (1998) Pathophysiology of thalassaemia. Baillière’s Clinical Haematology, 11, 127-146. doi:10.1016/S0950-3536(98)80072-3

[65]   Bartfay, W.J. and Bartfay, E. (2000) Iron-overload cardiomyopathy: evidence for a free radical—Mediated me- chanism of injury and dysfunction in a murine model. Biological Research for Nursing, 2, 49-59. doi:10.1177/109980040000200106

[66]   Schellhammer, P.F., Engle, M.A. and Hagstrom, J.W. (1967) Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation, 35, 631-637. doi:10.1161/01.CIR.35.4.631

[67]   Kremastinos, D.T., Toutouzas, P.K., Vyssoulis, G.P., Venetis, C.A. and Avgoustakis, D.G. (1984) Iron overload and left ventricular performance in beta thalassemia. Acta Cardiologica, 39, 29-40.

[68]   Sonakul, D., Pacharee, P. and Thakerngpol, K. (1988) Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Original Article Series, 23, 157-176.

[69]   Bannerman, R.M., Keusch, G., Kreimer-Birnbaum, M., Vance, V.K. and Vaughan, S. (1967) Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria. The American Journal of Medicine, 42, 476-486. doi:10.1016/0002-9343(67)90276-8

[70]   Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Ward, S.E., Agnew, J.E. and Hilson, A.J. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica, 84, 113- 117. doi:10.1159/000205046

[71]   Kremastinos, D.T., Tiniakos, G., Theodorakis, G.N., Katritsis, D.G. and Toutouzas, P.K. (1995) Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation, 91, 66-71. doi:10.1161/01.CIR.91.1.66

[72]   Cohen, A., Martin, M. and Schwartz, E. (1984) Depletion of excessive liver iron stores with desferrioxamine. British Journal of Haematology, 58, 369-373. doi:10.1111/j.1365-2141.1984.tb06096.x